Publications

Search our bibliography using the filters on the right-hand side.

Displaying 51 through 100 of 110 publications.

Aletaha D, Husni ME, Merola JF, Ranza R, Bertheussen H, Lippe R, Young P, Cappelleri JC, Brown TM, Ervin C, Hsu M-A, Fallon L. Treatment mode preferences in psoriatic arthritis: a qualitative multi-country study. Patient Prefer Adherence. 2020 Jun 8;2020(14):949-61. doi: 10.2147/PPA.S242336

Layton JB, Anderson-Smits C, Ritchey ME, Chavan S, Souayah N. Treatment patterns of a large US sample of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) patients. Poster presented at the 2020 6th EAN Congress Virtual Congress; May 23, 2020.

Anderson-Smits C, Layton JB, Ritchey ME, Hayden V, Sehinovych I, Chavan S, Souayah N. Patient and treatment characteristics of a large US sample of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) initiating Intravenous Immunoglobulin (IVIG) therapy. Poster presented at the 2020 Virtual American Academy of Neurology Annual Meeting (Conference cancelled); April 25, 2020. Toronto, Canada. [abstract] Neurology. 2020 Apr 14; 94(15 Supplement):4442.

Fernandez M, Mordin M, Neighbors M, Tzivelekis S. A targeted literature review on the burden of chronic inflammatory demyelinating polyneuropathy. Poster presented at the 2019 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Conference; October 16, 2019. Austin, TX. [abstract] Muscle Nerve. 2019 Sep; p.112.

Himmler S, Mueller M, Sherif B, Ostwald D. A case study applying a novel approach to estimate the social impact of a medical innovation - the use of secukinumab for psoriatic arthritis in Germany. Expert Rev Pharmacoecon Outcomes Res. 2019 Jul 29. doi: 10.1080/14737167.2019.1644169

DiBenedetti D, McLeod L, Williams N, Coles T, Tzivelekis S, Meckley LM. Development and validation of the IG Patient Experience with Treatment (IGPET), a novel patient-reported measure for individuals with primary immunodeficiency diseases. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 21, 2019. New Orleans, LA.

Ajmera M, Parikh R, Meyers J. Autoimmune disorders among adults with asthma: an economic outlook. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 21, 2019. New Orleans, LA.

DiBenedetti D, Tzivelekis S, Meckley L. Humanistic cost impacts associated with immunoglobulin replacement therapy among patients with primary immunodeficiency disease in the United States. Poster presented at the 2019 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 25, 2019. San Diego, CA. [abstract] J Manag Care Pharm. 2019 Mar; 25(3-a Suppl):S37.

Meckley L, Coles T, Williams N, DiBenedetti D, McLeod L. Experience with immunoglobulin treatment among patients with PIDD in the US. Poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting; February 22, 2019. San Francisco, CA. [abstract] J Allergy Clin Immunol. 2019 Feb; 143(2 Supplement):AB112. doi: 10.1016/j.jaci.2018.12.341

Coles T, Meckley LM, McLeod L, Williams N, DiBenedetti D, Devercelli G. Psychometric evaluation of the immunoglobulin patient experience with treatment (IgPET) in primary immunodeficiency diseases. Poster presented at the 25th Annual International Society for Quality of Life Research Conference (ISOQOL); October 26, 2018. Dublin, Ireland.

Coates L, Gossec L, Kirkham B, Sherif B, Gaillez C, Mpofu S, Jugl SM, Karyekar C, Gandhi KK. Minimal disease activity among active psoriatic arthritis patients treated with Secukinumab: 2-year results from a multicenter, randomized, double-blind, parallel-group, placebo-controlled phase III study. Arthritis Care Res (Hoboken). 2018 Oct;70(10):1529-35. doi: 10.1002/acr.23537

Buchanan V, Sullivan W, Graham C, Miles L, Jugl SM, Gunda P, Halliday A, Kirkham B. Cost effectiveness of secukinumab for the treatment of active psoriatic arthritis in the UK. Pharmacoeconomics. 2018 Jul;36(7):867-78. doi: 10.1007/s40273-018-0674-x.

Mease PJ, Gladman DD, Davenport EK, Zhou X, Guerette B, Teng L, Kaura S, Nash P. Improvements in work productivity with up to 104 weeks of apremilast monotherapy: results from a phase 3b, randomized, controlled study in biologic-naive subjects with active psoriatic arthritis. Poster presented at the 5th World Psoriasis & Psoriatic Arthritis Conference 2018; June 27, 2018. Stockholm, Sweden. [abstract] Acta Derm Venereol. 2018 Jun; 98(Suppl 219):14. Previously presented at the 2017 ACR/ARHP Annual Meeting. doi: 10.2340/00015555-2978

Goeree R, Chiva-Razavi S, Gunda P, Graham CN, Miles L, Nikoglou E, Jugl SM, Gladman DD. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective. J Med Econ. 2018 Feb;21(2):163-73. doi: 10.1080/13696998

Ajmera MR, Boscoe A, Mauskopf J, Candrilli SD, Levy M. Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica. J Neurol Sci. 2018 Jan;384(2018):96-103. doi: 10.1016/j.jns.2017.11.022

Kirkham B, Buchanan V, Sullivan W, Graham CN, Miles L, Jugl SM, Gunda P, Halliday A. Cost-effectiveness of secukinumab for the treatment of active psoriatic arthritis in the UK. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 6, 2017. Glasgow, Scotland.

Fischer A, Zimovetz E, Ling C, Esser D, Shoof N. Humanistic and cost burden of systemic sclerosis: a review of the literature. Autoimmun Rev. 2017 Nov;16(11):1147-54. doi: 10.1016/j.autrev.2017.09.010

Porter W, Mahajan P, Danysh HE, Chelius DC. Socioeconomic determinants of pediatric papillary thyroid cancer: a SEER database review. Poster presented at the 87th Annual Meeting of the American Thyroid Association; October 21, 2017. Victoria, Canada. [abstract] Thyroid. 2017 Oct; 27(S1):A135-6.

Mahajan P, Danysh HE, Chelius DC, Venkatramani R. Characteristics and outcomes of children and adolescents with low-risk papillary thyroid carcinoma in the SEER database. Poster presented at the 87th Annual Meeting of the American Thyroid Association; October 20, 2017. Victoria, Canada. [abstract] Thyroid. 2017 Oct; 27(S1):A92.

Mahajan P, Danysh HE, Chelius DC, Venkatramani R. Characteristics and outcomes of children and adolescents with high-risk papillary thyroid carcinoma in the SEER database. Poster presented at the 87th Annual Meeting of the American Thyroid Association; October 20, 2017. Victoria, Canada. [abstract] Thyroid. 2017 Oct; 27(S1):A92-3.

Carman WJ, Accortt NA, Anthony MS, Iles J, Enger C. Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use. Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1109-18. doi: 10.1002/pds.4261

Goeree R, Gladman D, Chiva-Razavi S, Gunda P, Graham CN, Miles L, Nikoglou E, Jugl SM. Cost-effectiveness analysis of secukinumab in psoriatic arthritis: a Canadian perspective. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A145.

Marzo-Ortega H, Halliday A, Jugl S, Mokashi S, Porter B, Talloczy Z, Sherif B, Williams N, Keat A. Impact of alternative definitions of treatment response on long-term efficacy of secukinumab in tumour necrosis factor alpha-naïve patients with active ankylosing spondylitis. Poster presented at the British Society for Rheumatology 2017; April 25, 2017. Birmingham, United Kingdom.

Emery P, Halliday A, Jugl S, Mokashi S, Porter B, Martin R, Sherif B, Williams N, Marzo-Ortega H. Week 12 response predicts long-term efficacy of secukinumab in patients with active ankylosing spondylitis independent of previous TNFi exposure. Poster presented at the British Society for Rheumatology 2017; April 2017. Birmingham, United Kingdom.

Martin SA, Chen K, Harris NI, Vera-Llonch M. Development of a patient-reported outcome measure for chronic hypoparathyroidism. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 1, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A679.

White M, Hogue S, Odom D, Cooney D, Bartsch J, Hollis K, Herrem C, Silvia S. EPIPEN4SCHOOLS® survey combined analysis: a comprehensive assessment of anaphylaxis in US schools. Presented at the 2016 AAP National Conference & Exhibition; October 22, 2016. Sacramento, CA.

Mease P, Coates LC, Kirkham B, McLeod LD, Mpofu S, Karyekar C, Gandhi K. Secukinumab improves minimal disease activity response rates in patients with active psoriatic arthritis: data from phase 3 FUTURE-2 study. Poster presented at the 10th International Congress on Spondyloarthritides; September 2016. Gent, Belgium. Previously presented at the 2016 Annual European Congress of Rheumatology (EULAR).

White MV, Hogue SL, Odom D, Cooney D, Bartsch J, Goss D, Hollis K, Herrem C, Silvia S. Anaphylaxis in schools: results of the EPIPEN4SCHOOLS survey combined analysis. Pediatr Allergy Immunol Pulmonol. 2016 Sep;29(3):149-54. doi: 10.1089/ped.2016.0675

White MV, Silvia S, Hollis K, Goss D, Odom D, Bartsch J, Hogue SL. EPIPEN4SCHOOLS® survey combined analysis: prevalence and triggers of anaphylactic events. Poster presented at the NASN 2016 48th Annual Conference; June 30, 2016. Indianapolis, IN. Previously presented at the 2016 AAAAI Annual Meeting.

Gossec L, Kvien TK, Conaghan PG, Ostergaard M, Canete J, Gaillez C, Mpofu S, Davenport E, Jugl S. Reduction in fatigue in patients with active psoriatic arthritis are sustained over 2 years: long-term results of two phase 3 studies with secukinumab. Poster presented at the 2016 European League Against Rheumatism Annual European Congress of Rheumatology (EULAR); June 2016. London, United Kingdom. [abstract] Ann Rheum Dis. 2016 Jun; 75(Suppl 2):351. doi: 10.1136/annrheumdis-2016-eular.2052

Hogue SL, Silvia S, Hollis K. EPIPEN4SCHOOLS® survey combined analysis: staff training and use of epinephrine auto-injectors. Poster presented at the NASN 2016 48th Annual Conference; June 2016. Indianapolis, IN. Previously presented at the 2016 ACAAI Conference.

Graham CN, Gunda P, Miles L, Jugl S, Palaka E, McBride D. A new cost-effectiveness framework for modeling ankylosing spondylitis treatments. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A234.

Hogue SL, Silvia S, Hollis K, Goss D, Odom D, Cooney D, White MV. EPIPEN4SCHOOLS® survey combined analysis: staff training and use of epinephrine auto-injectors. Poster presented at the 2016 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 19, 2016. San Francisco, CA. [abstract] J Manag Care Pharm. 2016 Apr; 22(4-a):S116. Previously presented at the 2016 ACAAI Conference.

Hogue SL, Silvia S, Hollis K, Wooddell MJ, Goss D, Odom D, Cooney D, White MV. EPIPEN4SCHOOLS® survey combined analysis: staff training and use of epinephrine auto-injectors. Poster presented at the 2016 ACAAI Conference; March 4, 2016. Los Angeles, CA.

Kan H, Nagar S, Patel J, Wallace DJ, Molta C, Chang DJ. Longitudinal treatment patterns and associated outcomes in patients with newly diagnosed systemic lupus erythematosus. Clin Ther. 2016 Mar;38(3):610-24. doi: 10.1016/j.clinthera.2016.01.016

Williame C, Rosillon D, Zima J, Angelo MG, Stuurman A, Vroling H, van Staa T, Boggon R, Bunge E, Pladevall-Vila M, Baril L. Risk of autoimmune diseases (AD) after human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine immunization in women aged 9 to 25 years in the United Kingdom: an observational cohort study. Poster presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA.

Andrews EB, Gilsenan AW, Midkiff KD, Harris DH. Comments on Bang et al.: the impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers. Osteoporos Int. 2015 May;26(5):1663-4. doi: 10.1007/s00198-014-3003-z

White MV, Goss D, Hollis K, Millar K, Silvia S, Siegel P, Bennett ME, Wolf RA, Wooddell M, Hogue S. EpiPen4Schools® survey: characteristics of anaphylaxis and common triggers. Poster presented at the 2015 AAAAI Annual Meeting; February 15, 2015. Houston, TX. [abstract] J Allergy Clin Immunol. 2015 Feb; 135(Suppl 2):AB212.

Harris DH, Midkiff K, Gilsenan A, Kellier N, Masica D, Andrews E. Eight-year results from the US osteosarcoma surveillance study. Poster presented at the 29th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2013. Montreal.

Kandala NB, Connock M, Grove A, Sutcliffe P, Mohiuddin S, Hartley L, Court R, Cummins E, Gordon C, Clarke A. Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis. BMJ Open. 2013 Jul 19;3(7):pii: e002.

Ben-L'amri M, McKenna SP, Wilburn J, Twiss J. Assessing quality of life in new regions of the world: further development of the PsAQoL. Poster presented at the 19th Annual Conference of the International Society for Quality of Life Research (ISOQOL); October 2012. Budapest, Hungary. [abstract] Qual Life Res. 2012 Oct; 21(S1):120.

McKenna SP, Wilburn J, Crawford SR, Aryamanesh M, Twiss J. New developments in the Ankylosing Spondylitis Quality of Life (ASQOL) scale. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 2011. Madrid, Spain. [abstract] Value Health. 2011 Nov; 14(7):A314.

Candrilli SD, Davis KL, Balkrishnan R, O'Brien S. Changes in rates of sickle cell disease-related inpatient stays and associated resource use among African Americans in the United States following approval of hydroxyurea. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France.

Candrilli SD, Kappelman MD, Karve SJ, Tennis PS, Andrews EB, Massie SE. Comorbidity burden among US pediatric patients with systemic lupus erythematosus and inflammatory bowel disease. Poster presented at the 2009 Pediatric Academic Societies' Annual Meeting; May 2009.

Doward LC, McKenna SP, Whalley D, Tennant A, Griffiths B, Emery P, Veale DJ. The development of the L-QoL: a quality of life instrument specific to systemic lupus erythematosus. Ann Rheum Dis. 2009 Feb;68(2):196-200. doi: 10.1136/ard.2007.086009

Plaza A, Navarro P, Garcia-Esteve LL, Ascaso C, Aguado J, Martin-Santos R. Pospartum depression and early life events: influences of the dysregulation of the pituitary-thyroid axis. Poster presented at the 15th AEP Congress; March 19, 2007. Madrid, Spain. [abstract] Eur Psychiatry. 22(Suppl 1):S243. doi: 10.1016/j.eurpsy.2007.01.812

Mines D, Gu Y, Novelli L, Lui Q, Gelfand J. Risk of CNS demyelinating diseases among patients with psoriasis and rheumatoid arthritis. Poster presented at the 2007 59th Annual Meeting of the American Academy of Neurology; May 2007. Boston, MA. [abstract] Neurology. 2007; 68(12, Suppl 1):A165.

Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15(5):308-18.

Maguire A, Arellano Felix M, Perez-Gutthann S, Arana A. Risk benefit modeling: the use of stochastic simulation for safety evaluations. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13(Suppl 1):S272.